These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 1826095)
1. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation. Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095 [TBL] [Abstract][Full Text] [Related]
2. Objective assessment of heparin requirements for hemodialysis in humans. Ireland H; Lane DA; Curtis JR J Lab Clin Med; 1984 Apr; 103(4):643-52. PubMed ID: 6230409 [TBL] [Abstract][Full Text] [Related]
3. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis. Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422 [TBL] [Abstract][Full Text] [Related]
4. [Long-term hemodialysis and changes in variables of coagulation and fibrinolysis]. Uchida Y Fukuoka Igaku Zasshi; 1991 Nov; 82(11):576-85. PubMed ID: 1774013 [TBL] [Abstract][Full Text] [Related]
5. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency. Herren T; Straub PW; Haeberli A Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646 [TBL] [Abstract][Full Text] [Related]
6. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation]. Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289 [TBL] [Abstract][Full Text] [Related]
7. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F Nephron; 2002; 92(3):589-600. PubMed ID: 12372942 [TBL] [Abstract][Full Text] [Related]
8. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation. Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253 [TBL] [Abstract][Full Text] [Related]
9. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450 [TBL] [Abstract][Full Text] [Related]
10. The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. Gabutti L; Ferrari N; Mombelli G; Keller F; Marone C J Nephrol; 2004; 17(6):819-25. PubMed ID: 15593057 [TBL] [Abstract][Full Text] [Related]
11. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit. Lucchi L; Ligabue G; Marietta M; Delnevo A; Malagoli M; Perrone S; Stipo L; Grandi F; Albertazzi A Artif Organs; 2006 Feb; 30(2):106-10. PubMed ID: 16433843 [TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222. Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924 [TBL] [Abstract][Full Text] [Related]
13. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions. Fareed J; Kumar A; Rock A; Walenga JM; Davis P Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364 [TBL] [Abstract][Full Text] [Related]
14. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456 [TBL] [Abstract][Full Text] [Related]
15. [Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases]. Murakoshi T Hokkaido Igaku Zasshi; 1982 May; 57(3):351-63. PubMed ID: 6957368 [TBL] [Abstract][Full Text] [Related]
16. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation. Seo JW; Kim HK; Kim JE; Park S; Cho HI Thromb Res; 2009 Feb; 123(4):565-72. PubMed ID: 18479738 [TBL] [Abstract][Full Text] [Related]
17. Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis. Clyne N; Lins LE; Egberg N Clin Nephrol; 1995 Apr; 43(4):260-7. PubMed ID: 7606881 [TBL] [Abstract][Full Text] [Related]
18. Indices of fibrinogen proteolysis and platelet activation during the resolution of pulmonary embolism. Yudelman I Thromb Haemost; 1987 Feb; 57(1):11-6. PubMed ID: 2954258 [TBL] [Abstract][Full Text] [Related]
19. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195 [TBL] [Abstract][Full Text] [Related]
20. The influence of dialyzer geometry on blood coagulation and biocompatibility. Lins LE; Boberg U; Jacobson SH; Kjellstrand C; Ljungberg B; Skröder R Clin Nephrol; 1993 Nov; 40(5):281-5. PubMed ID: 8281717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]